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Abstract 
Vaccinia virus (VACV) gene F5L was recently identified as a determinant of plaque morphology 
that is truncated in Modified Vaccinia virus Ankara (MVA). Here we show that F5L also affects 
plaque morphology of the virulent VACV strain Western Reserve (WR) in some, but not all cell 
lines, and not via previously described mechanisms. Further, despite a reduction in plaque size for 
VACV WR lacking F5L there was no evidence of reduced virus replication or spread in vitro or in 
vivo. In vivo we examined two mouse models, each with more than one dose and measured signs 
of disease and virus burden. These data provide an initial characterization of VACV F5L in a 
virulent strain of VACV. Further they show the necessity of testing plaque phenotypes in more than 
one cell type and provide an example of a VACV gene required for normal plaque morphology but 
not replication and spread. 
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Introduction 
Infection with vaccinia virus (VACV) disrupts numerous cellular pathways resulting in significant 
changes in cell morphology. Infection of confluent monolayers of many adherent cell lines with 
VACV results in the formation of large circular plaques due to a combination of cytopathic effects 
and migration of infected cells. Three groups of poxvirus genes affect plaque formation. Firstly the 
many poxvirus genes that are essential for virus replication are therefore required for plaque 
formation. Secondly, plaque formation is also reliant on spread of infectious extracellular virions 
(EV) mediated by actin tails. Therefore, loss of proteins involved either in morphogenesis or 
intracellular transport of wrapped virions (WV), or actin tail formation itself dramatically reduce 
plaque size despite production of high levels of mature virions (MV). A third group of genes are 
required for normal plaque morphology and size but less strongly affect virus output in vitro. 
Analysis of members of this third group of genes has led to mechanistic insight into cytoskeletal 
rearrangements required for cell migration (F11L) and attachment to the extracellular matrix (C2L 
and A55R)(Pires de Miranda et al., 2003; Beard, Froggatt, and Smith, 2006; Valderrama et al., 
2006; Arakawa et al., 2007; Arakawa, Cordeiro, and Way, 2007; Morales et al., 2008; Cordeiro et 
al., 2009; Handa et al., 2013).  
 
VACV mutants with reduced plaque size or altered plaque morphology typically show altered 
virulence. Examples include VACV strain Western Reserve (WR) C16 and B14 (VACWR010/209 
and VACWR196 respectively) both of which encode functions required for normal plaque size and 
for virulence (Chen, Jacobs, and Smith, 2006; Chen et al., 2008; Fahy et al., 2008). Likewise, 
VACVWR with deletions of BTB/kelch proteins, C2 or A55, form wild type sized plaques with 
indistinct borders and cause altered lesions following intradermal infection of mice (Pires de 
Miranda et al., 2003; Beard, Froggatt, and Smith, 2006). Beyond VACV, plaque size is positively 
correlated with case fatality rates for variola virus isolates within the same clade (Olson et al., 
2009). Data such as these have led to a conventional view that changes to plaque morphology will 
be mirrored by in vivo changes to virus replication, spread and/or virulence. 
 
We have recently identified F5L as another VACV gene that influences plaque morphology and 
spread during a study based on strain Modified Vaccinia virus Ankara (MVA) (Dobson and 
Tscharke, 2013). MVA fails to replicate on most mammalian cell lines (Carroll and Moss, 1997; 
Drexler et al., 1998), however using a marker rescue approach, Wyatt et al (1998) generated a set 
of recombinant MVAs (rescued MVAs) with improved replication on a range of mammalian cells. 
We identified F5L, which is truncated in MVA but repaired in some of the rescued viruses, as a 
gene responsible for significant differences in plaque morphology across this set of rescued MVA 
strains (Dobson and Tscharke, 2013). Further experiments found that while repair of F5 was 
associated with significant changes in plaque morphology it had no discernible effect on replication 
in vitro (Dobson and Tscharke, 2013). F5L remains poorly characterized, but an early description 
of the VACV HindIII F region and the most accurate VACV-genome wide transcriptomic study 
found that it is expressed early after infection (Roseman and Slabaugh, 1990; Yang et al., 2010). 
F5 is not a component of mature virions (MV) (Chung et al., 2006; Yoder et al., 2006; Resch et al., 
2007; Manes et al., 2008) and a large yeast-two-hybrid study found no interactions between F5 
and other VACV proteins (McCraith et al., 2000). 
 
It was possible that the role found for F5 in the context of MVA was influenced by one or more of 
the many other genetic changes in MVA compared to most virulent VACV strains. Further, studies 
of virulence based on viruses with the MVA genetic background will be complicated by the loss of 
many virulence functions, some known and others yet to be defined (Blanchard et al., 1998). 
Indeed a recent report demonstrated that the rescued MVAs were highly attenuated and the 
rescued strain with the largest plaque was no more virulent than MVA in an intranasal infection 
model, even in immunocompromised mice (Melamed et al., 2013). To address these issues, we 
explored the function of F5L in VACVWR. In this virulent VACV strain, F5 is required for normal 
plaque size and morphology in multiple cell lines, but was not required for replication or spread in 
any cells in vitro, nor for virulence in vivo. 
 
Results 
Conservation of F5 across the poxviruses and similarity to known proteins 
F5L (also annotated as VACWR044) encodes a 322 aa protein in VACVWR. F5 contains a 
predicted signal sequence, with a cleavage site between aa 20 and 21 (Signal P 3.0 (Bendtsen et 
al., 2004)) and a putative transmembrane domain at the carboxyl-terminus (aa 287-311) (TMHMM 
(Krogh et al., 2001)). Orthologs are found in all members of the orthopoxvirus genus for which 
genome sequence is available except ectromelia virus (Viral Orthologous Clusters, (Upton et al., 
2003)). The taterapoxvirus homolog is truncated to 193 aa and therefore lacks the putative 
transmembrane domain (GenBank Accession number NC_008291). No significant homologs are 
found outside the genus (BLASTp, E value <0.001). Beyond the poxviruses, the amino terminus of 
F5 contains a region with similarity to immunoglobulin V-set domain containing proteins, but this 
does not reach the significance threshold (E value=0.00036) (Pfam (Finn et al., 2010)). Variation 
exists amongst F5L homologs from various strains of VACV (Fig. S1). For example, F5L from the 
VACV strain referred to as Ankara, used to rescue MVA for growth on BS-C-1 cells (Wyatt et al., 
1998) and for our description of a role for F5 in the context of MVA (Dobson and Tscharke, 2013), 
encodes a 321 amino acid protein due to a 3 bp deletion. In addition to this difference, ten 
nucleotide substitutions are present in Ankara F5L compared with VACVWR, resulting in four 
amino acid changes. 
 
Deletion of F5L affects plaque morphology but not replication of VACVWR 
A VACVWR strain with 86% of the F5L ORF deleted (VACVWRΔF5L) and a revertant 
(VACVWRF5Lrev) were made, demonstrating that F5 is non-essential for VACVWR growth in 
culture. However, plaques formed by VACVWRΔF5L were approximately 30% smaller than the 
parent or VACVWRF5Lrev on BS-C-1 cells. Cell clearance from the center of plaques was reduced 
and the distinctive halo of contracted cells that usually surround VACV plaques (Cordeiro et al., 
2009) was absent (Fig. 1a-d). Further, live microscopy showed that the expansion rate of plaques 
was slower in the absence of F5 (Fig. 1c). VACVWRΔF5L also formed smaller plaques on RK13, 
IEC-6, and 293A cells (Fig. 1b,e,f). By contrast, we observed no difference in plaques formed on 
primary human foreskin fibroblasts, BHK-21 or the murine cell line NIH/3T3 (Fig. 1b, and data not 
shown). 
 
To determine whether loss of F5 affected virus replication, a high multiplicity (m.o.i. = 5) growth 
experiment was done (Fig. 2a). This found no decrease in replication associated with the loss of 
F5. We then used multiple-step experiments (m.o.i.=0.01) to measure replication and spread. 
These found that deletion of F5L had no effect on either cell associated, or supernatant virus yield 
in BS-C-1 (Fig. 2b) or primary human foreskin fibroblasts (HFF) (data not shown). To probe 
replication and spread more stringently, inocula were reduced to approximately 50 p.f.u. in a 9.5 
cm2 culture of BS-C-1, so that spread would not be inhibited by a lack of infectable cells. Even in 
this experiment with six replicates, no statistically significant difference in virus output per plaque 
was across the parent, VACVWRΔF5Land VACVWRF5Lrev or between any pair of viruses at 72 
hours post infection (h.p.i.)(Fig. 2c). This last experiment was repeated and again no significant 
differences were found. Taken together, these experiments suggest that F5 has no discernable 
role in VACVWR replication or spread in in vitro culture, even on a cell line where it is required for 
normal plaque morphology. 
 Localization of the F5 protein in infected cells 
In order to test the predicted cell membrane localization of F5 we produced VACVWR/F5LGFP in 
which the native F5 was replaced with an F5-eGFP fusion. This virus had a plaque phenotype 
similar to VACVWR on BS-C-1 cells (Fig. S2), demonstrating that F5 function is intact in this virus. 
There was diffuse fluorescence in cells infected with VACVWR/F5LGFP at several times after 
infection up to 8 h.p.i., but across multiple images we were unable to determine the localization 
with any certainty. The only common pattern that was evident across all images emerged from 6-8 
h.p.i. and was an enrichment of eGFP at the periphery of the cell where thin cytoplasmic 
extensions are evident. This localization was restricted to regions in contact with neighboring cells, 
suggesting cell–cell contact might stabilize or recruit F5 (Fig. 3). This pattern of staining was not 
seen in cells infected by VACVWR expressing eGFP not fused to F5L, but was confirmed for F5-
eGFP by total internal reflection fluorescence (TIRF) microscopy (not shown). To further define the 
location of F5-eGFP fluorescence, cells were stained for actin (phalloidin and cortactin), the cell-to-
cell junction marker β-catenin, or phosphotyrosine as a marker of focal adhesions. In each case 
projections marked with eGFP were noted, but these failed to co-localize with any of the host cell 
markers (Fig.3). Finally, F5-eGFP did not colocalize with B5, a marker for enveloped virus (EV) or 
the virus factory, as shown by the DNA stain DAPI, where intracellular mature virus is assembled 
(Fig. 3 row 3 and other rows respectively). 
 
F5L is not required for actin tail formation, Ca2+ independent cell adhesion or cell migration 
Deletion of viral genes has identified three mechanisms associated with alterations in VACV 
plaque size and appearance which are not always matched by a measureable reduction in virus 
yield: 1) ability to make actin tails, 2) loss of adhesion of infected cells in the absence of Ca2+ and 
3) altered cell migration of infected cells. We considered whether deletion of F5 might act by these 
mechanisms, addressing each in turn below. 
 
1) VACV morphogenesis is complicated and several forms of infectious virus are made. The form 
of virus implicated in virus spread in vivo is wrapped with an additional membrane (EV) and is able 
to be released from infected cells, or propelled into a neighboring cell by an actin tail (Roberts and 
Smith, 2008; Welch and Way, 2013). Loss of certain proteins incorporated into the outer 
membrane of EV dramatically reduces plaque size either as a result of decreased EV production, 
reduced infectivity of the virus released, or decreased production of actin tails (Blasco and Moss, 
1991; Duncan and Smith, 1992; Engelstad and Smith, 1993; Wolffe, Isaacs, and Moss, 1993; 
McIntosh and Smith, 1996; Wolffe et al., 1997; Roper et al., 1998; Ward and Moss, 2001). 
Likewise, viruses lacking other genes required for efficient assembly and transport of WV or for 
actin tail formation, have very small plaques (Rodriguez and Smith, 1990; Parkinson and Smith, 
1994; Wolffe, Weisberg, and Moss, 1998; Zhang, Wilcock, and Smith, 2000; van Eijl et al., 2002; 
Domi, Weisberg, and Moss, 2008; Dodding et al., 2009; Morgan et al., 2010). We noted that the 
effect of F5L on plaque size was not as strong as published reports for these genes. Furthermore, 
F5 appeared not to be required for EV production and release because similar amounts of virus 
were found in the supernatant of cells infected with VACVWRΔF5L, its parent and the revertant 
(Fig 2b). When ‘comet’ plaque assays were done with liquid overlay so that secondary plaques can 
be formed by released EV , the morphology of the primary and small secondary plaques but not 
the extent of secondary plaque formation were dependent on F5 (data not shown). Finally, actin 
tails were observed directly for our viruses. As shown in figure 4a, no significant difference in actin 
tail length was found between VACVWRΔF5L and VACVWRF5Lrev (Fig. 4a). 
 
2) When Ca2+ is depleted from the growth medium, uninfected BS-C-1 cells lose the ability to 
adhere to the extracellular matrix and round up, but this process is inhibited by VACV infection 
(Sanderson and Smith, 1998). The A55 and C2 proteins of VACVWR are required for VACV-
induced Ca2+-independent cell adhesion. Like F5L, deletion of C2L or A55R alters plaque 
morphology without substantially affecting in vitro replication and plaques formed by 
VACVWRΔF5L appeared similar to published images of the VACVWR mutants, vΔC2 and vΔA55, 
so we wondered if F5 was required for Ca2+-independent adhesion (Pires de Miranda et al., 2003; 
Beard, Froggatt, and Smith, 2006). BS-C-1 cells were infected with VACVWR, VACVWRΔF5L, or 
VACVWRF5Lrev for 18 hours before Ca2+ was sequestered by adding EDTA to the medium and 
then adhesion of cells was monitored over 20 min (Fig. 4b). Uninfected cells rapidly lost adhesion 
and rounded up. By contrast, the majority of virus-infected cells remained strongly adherent and 
the absence of F5 had no effect on this Ca2+-independent adhesion. 
 
3) VACV infection induces migration of cells and protein F11 is involved in the cytoskeletal 
rearrangements required for this motility (Valderrama et al., 2006; Morales et al., 2008; Cordeiro et 
al., 2009; Handa et al., 2013). As a result, deletion of F11L from VACVWR reduces plaque size 
(Morales et al., 2008; Cordeiro et al., 2009; Handa et al., 2013) and cells infected with MVA, in 
which F11L is fragmented, do not migrate into a wound made in a monolayer of serum starved BS-
C-1 cells (Valderrama et al., 2006; Zwilling et al., 2010). Initial live microscopy suggested that F5 
was not required for cell motility (not shown) but to test this more quantitatively we measured 
migration of BS-C-1 cells infected with VACVWRΔF5L, VACWRF5Lrev, or VACVWR using a 
scratch wound assay (Fig. 5a&b). Compared to mock-infection, all viruses induced significant 
migration of cells into the wound, irrespective of deletion of F5L. To ensure that this assay was 
sensitive to impairment of migration, we extended the assay to include several viruses based on 
MVA made in the process of mapping F5 as a determinant of plaque morphology in this strain. 
These viruses were: v51.2/F11LGb, in which F11L was repaired; v51.2/F5LGb and v51.2/F5L, in 
which F5L was repaired; v51.2/F5L-F11L, in which F5L and F11L were repaired ((viruses with ‘Gb’ 
in their name retain a GFP/bsd selectable marker downstream of the repaired gene; Dobson and 
Tscharke, 2013)) (Dobson and Tscharke, 2013). In agreement with the literature, only cells 
infected with viruses that had an intact F11L gene migrated into the wound. Presence or absence 
of F5 had no impact on migration either alone or in combination with F11 across this set of viruses 
(Fig. 5c). 
 
Virus infection is needed for F5 stability, but the predicted cytoplasmic tail is not required 
for function in vitro 
In order to study the effect of F5 expression on uninfected cells, we produced two F5-eGFP fusions 
expressed from the CMV IE promoter. The fusions contained either a full length (322 aa) or 
truncated (218 aa) F5L from VACVWR and were tagged on their c-termini with eGFP (pEGFP-
N1::F5L and pEGFP-N1::F5L218, respectively). F5L218 contains at Ser218Pro mutation such that 
the protein produced is identical to the predicted MVA F5 homolog (MVA034), and lacks 104 aa of 
the c-terminus, including the putative transmembrane domain. No differences in cell morphology 
were observed between 293A cells transfected with pEGFP-N1::F5L, pEGFP-N1::F5L218 or the 
empty control vector (not shown). The brightness of fluorescence in cells transfected with these 
constructs was in the order, empty pEGFP-N1 > pEGFP-N1::F5L218 F5 >> pEGFP-N1::F5L. To 
test if F5-eGFP instability in uninfected cells was contributing to the weak fluorescence, cells were 
mock-infected or infected with VACVWRΔF5L, 3h after transfection (Fig. 6a). Infection greatly 
increased fluorescence in cells expressing full length F5-eGFP, despite this construct being under 
control of the CMV IE promoter. By contrast and as expected for genes transcribed from the 
nucleus, eGFP fluorescence from theF5L218-GFP and the empty vector control construct was 
reduced by VACV infection. Thus the order of brightness after VACV infection was pEGFP-N1::F5L 
>> empty pEGFP-N1 and pEGFP-N1::F5L218 F5. In further experiments, F5L-eGFP brightness, 
but not that of the other two constructs was improved by VACVWR infection in the presence of 
AraC (data not shown). Together these experiments suggest that full length F5 requires another 
function expressed early in VACV infection for stability in cells, but this depends on sequences in 
F5L from WR that are not present in the truncated version expressed by MVA. 
 
Next, a complementation assay was used in which F5L fused to GFP was expressed from a 
plasmid under its natural promoter in cells infected by VACVWR or VACVWRΔF5L to determine if 
any domains were dispensable for function. Similar complementation assays have been used by 
others, including for genes with VACV early promoters, even though the early transcription factors 
are thought to be mostly sequestered in the virus cores (Cochran, Mackett, and Moss, 1985; 
Valderrama et al., 2006). The plasmid also encoded mCherry under the VACV strong synthetic 
promoter (pSS), which was brighter than F5-eGFP to more easily identify cells that received virus 
and the plasmid at low magnification. A plasmid containing F5-eGFP, but not the empty vector was 
able to rescue the plaque defect of VACVWRΔF5L on 293A cells demonstrating expression of 
functional F5 (Fig. 6b). Next, we tested the ability of a set of plasmids expressing F5-eGFP with 
regions of F5 deleted to rescue the plaque defect of VACVWRΔF5L. The predicted features of F5 
covered by these deletions were the signal sequence, the extracellular domains (broken into four 
segments) and the short cytoplasmic tail (Fig. 6c). Of these constructs, only the cytoplasmic tail 
deletion was still able to rescue the plaque size of VACVWRΔF5L, but eGFP fluorescence was 
always seen (Figure S3). These experiments suggest that the putative cytoplasmic tail is not 
required for the function of F5 in plaque morphology. 
 
F5L does not affect VACV pathogenesis, replication or spread in mice 
We examined the role of F5 in VACV virulence using two murine models of infection. First, BALB/c 
mice were infected intradermally with VACVWR, VACVWRΔF5L or VACVWRF5Lrev and lesion 
size monitored over 21 days (Fig. 7a). All viruses produced lesions at the infection site, but there 
was no difference in size between VACVWRΔF5L and controls. Virus replication over the first five 
days was also tested in this model, with doses of 1×104 p.f.u. and 1×102 p.f.u.. A titer of around 
1×107 p.f.u. was achieved irrespective of inoculum or virus, showing that F5 does not increase 
VACV replication in vivo in mice (Fig. 7b). 
 
Second, the intranasal model of infection was used. Three experiments were done with a dose of 
1×104 p.f.u. and there were no statistically significant differences in weight loss or number of mice 
that were euthanized due to loss of >30% of starting weight between VACVWRΔF5L and the 
control viruses (Fig 8a). A lower dose of 1×103 p.f.u. was then used to tease out any small 
difference between viruses, but again no consistent phenotype was found for VACVWRΔF5L (Fig. 
8a). Virus titers were measured at three, seven and 10 days after intranasal infection with 1×104 
p.f.u. of VACVWR, or VACVWRF5Lrev, examining lungs, brain, spleen (Fig. 8b), ovaries and liver 
(not shown). No significant difference in titer was found between the groups of mice for any organ 
at any time. Finally we tested several parameters of immunity in mice infected intranasally with 
VACVWRΔF5L and controls. There were no differences in: a) the total VACV-specific IgG 
response as measured by ELISA (Tscharke, Reading, and Smith, 2002); b) the memory CD8+ T 
cell response in the spleen as measured by production of IFN-γ after stimulation with VACV 
peptide epitopes (Flesch, Wong, and Tscharke, 2012; Flesch et al., 2012); c) infiltrates present in 
brochoalveolar lavage taken at various times after infection (Reading and Smith, 2003) (data not 
shown). 
 
Discussion 
We demonstrate here that VACV gene F5L is a determinant of plaque morphology in VACVWR 
when grown on a subset of cell lines tested, but does not contribute to virus replication in vitro in 
these same cells or to pathogenesis in mice. Taken at face value, smaller plaques in the absence 
of F5 suggest that this protein is required for normal spread of virus. However, no detectable 
change to replication in vitro was found despite using very low input titers to maximize the 
influence of virus spread. In addition, there was no defect in the ability of VACVWRΔF5L to 
replicate at primary sites of infection in mice, as seen in skin and lungs after intradermal and 
intranasal infection respectively, nor was there a defect in virus dissemination. In the case of the 
intradermal infection the above held true where the inoculated dose was as low as 100 p.f.u. and 
virus growth exceeded five orders of magnitude in five days, a very robust test of replication in 
vivo. It remains possible that deletion of F5L is associated with a very subtle reduction in virus 
production or spread that was beyond our sensitivity to dissect, but it is unclear that such a small 
difference would be important for the outcome of infection. Another important point highlighted by 
this study is that the effects of virus genes on plaques can be cell type-specific. We observed no 
difference in plaque size or morphology between VACVWRΔF5L and the wild type VACVWR when 
grown on BHK-21 (hamster), NIH/3T3 (mouse), or HFF (human), in contrast to the clear and 
reproducible differences seen for BS-C-1 (African green monkey), RK13 (rabbit), IEC-6 (rat) and 
293A (human) (Fig.1 and 6b). A further set of cell lines including HeLa (human), vero (African 
green monkey), L-cells (mouse) and L-Db (derivative of L-cells) made small and relatively variable 
plaques, or only foci, with all viruses making assessement of morphological differences associated 
with F5 inconclusive. There is no obvious species specificity across this wide range of cells, but 
some corellation with cell shape was noticed: F5 affected the round, regular plaques formed on 
cells that have cobble-stone or cuboid shapes when confluent and uninfected. By contrast, F5 had 
no affect on cells with more elongated (primay fibroblastoid-like) forms when confluent and on 
which VACV makes somewhat irregular plaques. This observation may have some relevance for 
the function of F5. 
 
A range of VACV genes have been characterized as being required for normal plaque morphology 
but when deleted have a minor (less than 10-fold) or undetectable effect on virus yield in multiple 
step growth curves. These include A55R, C2L (indistinct borders on BS-C-1) (Pires de Miranda et 
al., 2003; Beard, Froggatt, and Smith, 2006); C11R (10-30% smaller plaques on BS-C-1) (Buller et 
al., 1988), VACVWR010/209 (approximately 20-30% smaller plaques on BS-C-1 and RK13) (Fahy 
et al., 2008), O1L (plaques approximately 50% smaller on 293A) (Schweneker et al., 2012) and 
VACWR196 (smaller plaques on BSC-1 (20%) and CV-1(40%)) (Chen, Jacobs, and Smith, 2006). 
However, in each case viruses lacking these genes had altered pathogenesis in at least one model 
of infection in mice. In contrast for F5, over a total of six experiments across two models, no 
consistent role in virulence was observed, nor could an influence of this protein be found on three 
parameters of the immune response. The only other VACV protein associated with a plaque 
phenotype and not virulence is another membrane associated protein, A38, but pathogenesis was 
only assessed in a single model (Parkinson, Sanderson, and Smith, 1995). There are a range of 
other VACV genes for which deletion does not change pathogenesis in mice, for example A45R, 
B9R and B12R, but in these cases there is a similar lack of phenotype for the deletion virus in vitro 
(Banham and Smith, 1993; Almazan, Tscharke, and Smith, 2001; Price, Tscharke, and Smith, 
2002; Tscharke, Reading, and Smith, 2002). An example of a VACV protein with a known function 
that fails to alter pathogenesis in well controlled studies in mice is B8. B8 binds IFNγ from many 
species, but not mice, explaining its lack of function in mouse models (Alcamí and Smith, 1995; 
Symons et al., 2002). However, the B8R ortholog in the mouse-specific pathogen ectromelia virus 
does bind mouse IFNγ and deletion from this virus reduces virulence (Sakala et al., 2007). We 
speculate that F5 may lack a binding partner in this species, in support of this we saw no plaque 
defect in the absence of F5 on mouse NIH/3T3 cells, although we did observe a difference on 
another rodent cell line, IEC-6. It is interesting to note that ectromelia virus, a the mouse-specific 
orthopoxvirus lacks an F5L homolog. However, at the same time a role for virulence in mice has 
been shown for VACV genes K7R and A40R that are fragmented and therfore also non-functional 
in ectromelia virus (Tscharke, Reading, and Smith, 2002; Benfield et al., 2013). It remains unlikely 
that VACV would maintain a gene that has no role in an in vivo setting, therefore it may be of value 
to investigate  F5 function in another host species. Assuming such a function is found, it would be 
of interest to determine if it can be related in any way to the role for F5 revealed in plaque 
morphology here.  
 
While we have not defined how F5 contributes to plaque formation, its role is non-redundant and its 
mode of action is distinct from previously defined mechanisms. Firstly, there was no evidence that 
F5 plays any role in virion morphogenesis, EV release or actin tail formation. Secondly, unlike F11, 
F5 did not affect cell motility as captured by a scratch wound assays. Finally, unlike C2L or A55R, 
deletion of F5L from VACVWR does not reduce Ca2+-independent binding of cells to extracellular 
matrix. From the predicted structure, apparent localization to cell-cell contacts and lack of 
requirement for the putative intracellular portion we speculate that F5 functions via interactions with 
proteins on neighboring cells or extracellular matrix elements. However, this remains to be 
determined. 
 
In summary, we identify F5 as a determinant of plaque phenotype in a virulent strain of VACV and 
the data presented provide a foundation for further work on this previously uncharacterized protein. 
Finally, our investigations of F5L are a reminder that small plaque phenotypes should be checked 
in multiple cell lines cannot always be assumed to be a correlate of virus replication and spread. 
 
Methods 
Cells and virus 
All cells were maintained in Dulbecco’s modified Eagle medium (DMEM; Gibco/Invitrogen) with L-
glutamine and 10% FBS (D10), except for BHK-21 (Minimum Essential Medium (Gibco/Invitrogen) 
with L-glutamine and 10% FBS). Lipofectamine 2000 (Invitrogen) was used for all transfections. 
VACV stocks were grown in BHK-21 in DMEM with L-glutamine and 2% FBS (D2) and purified by 
centrifugation through a 36% sucrose cushion. Virus titers were determined by plaque assay on 
BS-C-1. 
 Plasmid construction 
PCR was used to generate inserts for InFusion (Clontech) or conventional cloning. In descriptions 
below, PCR primers for a) InFusion contain 15 bp matching flanking vector sequence (underlined) 
or a neighboring insert (bold); b) conventional ligations include restriction enzyme sites (italics). 
 
Generation of recombinant VACV 
General strategy: All recombinant VACV were produced by infection of 293A cells with the 
appropriate parent virus (m.o.i.= 0.05) followed by transfection 1 hour later with 1 µg of plasmid 
DNA. After 2 hours at 37°C transfection media was replaced with 2 ml D2. Cells were harvested 2 
days later. Plaque purification was carried out on BS-C-1 in phenol-red free D2-CMC. PCR 
screening and sequencing was used to confirm the correct modification had occurred and identify 
plaque picks free of parental virus. Two independent recombinant viruses were isolated from 
parallel infection/transfection experiments. 
VACVWRΔF5L and VACVWRF5Lrev: VACVWRΔF5L was engineered using transient dominant 
selection for the GFP-bsd marker gene from plasmid pSSGb (Wong et al., 2011). Sequences 
flanking F5L were amplified from VACVWR DNA with: Left flank: F5LLfwd: 
CAGTGTGCTGGAATTCTCACTATTCCGTCACTGGCTG and 
TTAAACCGCATCAAGCAGCACCCATGAATGTCGAT; Right: CTTGATGCGGTTTAATAAATGTT 
and F5LRrev: GATATCTGCAGAATTCTGCTGTGGTAGATTCTGTGACG. The last 134bp of F5L 
were preserved to maintain the promoter of F4L. VACVWRF5Lrev was produced by recombination 
between a linearized pSSGb vector containing the full F5L reading frame plus homology arms 
(PCR product of F5LLfwd and F5LRrev) and the VACVWRΔF5L genome. 
VACVWR/F5LGFP: To produce an eGFP-tagged version of the F5 protein, a plasmid construct 
(pSSmCB::F5LGFPnoM) was created with F5L fused to the 5’ end of EGFP (without initiation 
codon), plus the left and right flanking sequences used in the production of VACVWRΔF5L. The 
left flank (homL) was amplified from VACVWR DNA using 
TCTAGAGTCGCGGCCTCACTATTCCGTCACTGGCTG and 
ACAAGTAAAGCGGCCTTGTAGTGATTGCGGCGAT and cloned into pEGFP-N1 linearized with 
NotI; producing pEGFP-N1::homL. The eGFP gene from the second codon plus homL, were then 
amplified using pGFP: GTGAGCAAGGGCGAGGAG and F5LLfwd. The F5L ORF along with the 
right homology arm were amplified from VACVWR DNA using 
CTCGCCCTTGCTCACGTTATCTATATGCCTGTACTTGGAT and F5LRrev. The eGFP-homL and 
F5L PCR products were cloned into the unique EcoRI site in the MCS of pSSmCB (pSSGb from 
Wong et al., 2011 with eGFP replaced by mCherry). After recombination with VACVWRΔF5L, 
GFP+ plaques with wild type plaque morphology were selected.  
 
Evaluation of VACV plaques 
Plaque size: Confluent cell monolayers in six-well plates were infected with 50 p.f.u. virus. After 2 
hours at 37°C, the inoculum was replaced with semisolid D2+0.4% (w/v) carboxy-methyl cellulose 
(D2-CMC). Cells were fixed and immunostained with anti-MVA antibody followed by an anti-rabbit 
secondary antibody conjugated to horseradish peroxidase (Staib, Drexler, and Sutter, 2004). 
Plaque-expansion speed: Confluent BS-C-1 monolayers were infected with 50 p.f.u in glass-bottom 
six-well plates (MatTek). After 1 hour, cells were washed with PBS and Leibovitz's L-15 
(Invitrogen) with L-glutamine and 10% FBS was added. Plaques were identified in the monolayers 
from 14 h.p.i. and the leading-edge of each plaque was imaged every hour from 16 to 56 h.p.i. 
using an Olympus CellR Live-Cell Microscope (5x objective). Plaque areas and expansion speeds 
(µm hr-1) were calculated for each virus strain using Image J (v1.46j) (Rasband, 1997-2012). 
 
 Replication in vitro 
Confluent monolayers in six-well plates were infected with either 1x104 p.f.u. (multiple step growth 
curve ; m.o.i.=0.01) or 5x106 p.f.u (single step growth curve ; m.o.i.=5) virus in 1 ml D2. After 1 
hour at 37°C, unabsorbed virus was removed, cell monolayer washed once, and 2 ml fresh media 
added. 0h samples were harvested immediately after addition of fresh media. Further wells were 
harvested at the indicated time points. Cells were harvested into existing media, centrifuged at 
931xg for 10 minutes to separate cell-associated and supernatant virus, which were titrated 
separately. To calculate mean virus output per plaque, 9.5 cm2 wells of confluent BS-C-1 were 
infected with 500 µl of virus diluted to 1x102 p.f.u./ml in D2. After 90min, the inoculum was replaced 
with 2 ml D2 without CMC (6 wells per virus), or D2-CMC (3 wells per virus). 72 h.p.i. wells without 
CMC were harvested and virus titrated. Wells with D2-CMC were stained with crystal violet and 
plaques counted. 
 
Antibodies and fluorescent chemicals 
Primary antibodies used for immunofluorescence assays were: anti-B5 (Schmelz et al., 1994), anti-
phosphotyrosine (4G10; Chemicon), anti-cortactin (4F11, Upstate Biotechnology), anti-ß-catenin 
(610154, BD Transduction Laboratories). The secondary antibodies (Invitrogen) were: Alexa Fluor 
568-conjugated goat anti-mouse IgG, Alexa Fluor 568-conjugated goat anti-rabbit IgG, Alexa Fluor 
350-conjugated goat anti-rat IgG. Fluorescent chemicals used were DAPI (Sigma-Aldrich) (1 µg ml-
1) and Alexa Fluor 568-phalloidin (Invitrogen) (1:300 dilution). All antibodies were diluted in 
blocking buffer (1% BSA and 2% FBS in cytoskeletal buffer (CB) [10 mM MES buffer, 0.15 M NaCl, 
5 mM EGTA, 5 mM MgCl2, 50 mM glucose, pH 6.1]) 
 
Immunofluorescence microscopy 
Cells were seeded on glass coverslips, infected with appropriate viruses and fixed at 8 h.p.i. with 
3% paraformaldehyde (PFA) in CB for 10 min at room temperature. Before staining, cells were 
permeabilized with 0.1% Triton X-100 in CB (or not permeabilized as indicated). Cells were 
incubated in blocking buffer for 20 min, suitable primary antibodies for 40 min, washed three times 
in PBS, then incubated in secondary antibodies for 20 min. The coverslips were mounted on a 
glass slide with 1% (w/v) p-phenylenediamine (Sigma-Aldrich) in Mowiol mounting medium (10% 
(w/v) polyvinyl alcohol 4-88 [Sigma-Aldrich], 25% (w/v) glycerol, 0.1 M Tris, pH 8.5). Fluorescence 
was performed with an Olympus microscope BX51 with filter sets 31001, 31002, and 31013v2 
(Chroma). Actin-tail lengths were measured with Image J (v1.46j). 
 
Wound healing assays 
Confluent BS-C-1 cells on glass coverslips were serum starved in DMEM without FBS (D0) for 2 
hours, then infected (m.o.i.= 5). 1 h.p.i., wounds were created with a yellow tip and cells were 
washed in PBS and rescued in D0. Cells were fixed at 24 h.p.i. with 3% PFA in CB for 10 min, 
stained with DAPI and Alexa Fluor 568-phalloidin and mounted (as described above). All wounds 
were imaged with an Olympus microscope BX51 (10x objective), and an average wound size was 
calculated for mock infected cells. The number of cells containing DAPI stained nuclei within each 
wound were counted.  
 
Calcium independent cell adhesion 
Extracellular calcium was depleted by addition of EDTA (Sanderson and Smith, 1998). Confluent 
BS-C-1 monolayers were infected with the appropriate virus (m.o.i.= 3). 18 h.p.i. cells were washed 
three times with PBS, then 1 ml of PBS containing 10 mM EDTA was added to each well. Cells 
were incubated at 37°C for 3, 10 or 20 minutes. Photographs of three randomly selected fields 
were taken on a phase contrast microscope (100× magnification). Rounded up and adherent cells 
in the top left quadrant of each image were counted (155-450 cells). 
 
Transient rescue of VACVWRΔF5L plaque morphology 
pSSmCB::F5LGFP encodes the full length F5L-GFP fusion under the F5L promoter. F5L-GFP 
fusion and promoter were amplified from pSSmCB::F5LGFPnoM with EGFPstop: 
CAGTGTGCTGGAATTCTTACTTGTACAGCTCGTCCATG and F5LRrev, and cloned into 
pSSmCB linearized with EcoRI. From pSSmCB::F5LGFP five further plasmids were constructed by 
amplification of the whole plasmid using phosphorylated primers. Plasmids contained deletions of 
amino acids (aa) 2-17, 25-69, 75-144, 145-225, or 226-261. A plasmid containing F5L-GFP with a 
deletion of aa 315-322 was produced by splice overlap PCR using: 
CTCGCCCTTGCTCACTCTTTTGTACATCGATATCGC and F5LRrev, and EGFPstop and pGFP 
(external primers in bold), followed by cloning into pSSmCB linearized with EcoRI. 293A cells were 
infected with 50-100 p.f.u. of VACVWR or VACVWRΔF5L, then transfected 1 hour later with 2 µg 
of plasmid DNA. Transfection media replaced after 3.5 hours with phenol-red free D2-CMC. 48 
h.p.i. fluorescent plaques were photographed. 
 
Expression of F5 in uninfected cells 
Full length (F5L) or truncated (F5L218) F5L, amplified from VACVWR DNA with: 
CGCGGGCCCGGGATCAACATTTATTAAACCGCATCAAG and either F5full: 
GGCGACCGGTGGATCGTTATCTATATGCCTGTACTTGGAT or F5218: 
GGCGACCGGTGGATCTGGAAACAGATAACAAGAAAACTCGTC, were cloned into pEGFP-N1. 
293A cells were transfected with 2 µg of pEGFP-N1, pEGFP-N1::F5L, or pEGFP-N1::F5L218. 3hr 
post transfection, media was replaced with D2 for uninfected wells or VACVWRΔF5L or MVA 
(m.o.i= 5). 1 h.p.i. inoculum was replaced with 2 ml / well phenol-red free D2. After overnight 
incubation at 37°C, cells in the media were collected, while attached cells were washed with PBS 
and then removed using trypsin. Pooled cells were washed once with PBS, fixed using 1% PFA, 
and washed. eGFP fluorescence was measured using an LSR II flow cytometer (BD Biosciences) 
and data analyzed using FlowJo software (Tree Star Inc.). For inhibition of intermediate and late 
gene expression, overnight media contained 40 µg ml-1 AraC. 
 
Mice and infections 
Mice were housed and all experiments carried out in compliance with ethical requirements under 
approval from the Animal Ethics and Experimentation Committee (ANU). Specific pathogen-free, 
female BALB/c mice were obtained from ARC (Perth, Australia) or APF (Canberra, Australia). For 
pathogenesis experiments, 8 week old mice were anesthetized by inhalation of isofluorane (4% in 
medical-grade oxygen at 0.8 litres/min) and intradermally injected with 1x104 p.f.u. or 1x102 p.f.u. in 
10 µl PBS in the left ear pinnae (Tscharke and Smith, 1999; Lin, Smith, and Tscharke, 2012), or 
infected intranasally with 1x104 p.f.u. or 1x103 p.f.u. in a total of 20 µl of PBS (10 µl per naris). For 
the dermal model, lesion sizes were estimated daily as described previously (Tscharke and Smith, 
1999; Lin, Smith, and Tscharke, 2012). After intranasal infection mice were weighed daily and 
monitored for signs of infection. Severely ill mice (clinical score >6) or those that lost more than 
30% of baseline body weight that did not have an improving clinical score were euthanized. 
 
Titration of virus from organs 
The infected ears of intradermally infected mice were collected on day 5 p.i.. Organs were 
collected from intranasally infected mice at days 3, 7 or 10 p.i.. Ears or organs were homogenized 
in D2. Homogenates were frozen and thawed three times and sonicated for 20 sec three times, 
before titration. 
 
Statistical analysis 
Statistical comparisons were done using Prism Software (version 5.01; GraphPad). 
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Figure Legends 
Fig 1: Deletion of F5L affects plaque phenotype on several cell lines. Plaque formation on BS-
C-1, RK13, IEC-6  or NIH/3T3 cells by VACVWR, VACVWRΔF5L and VACVWRF5Lrev. (a&b) 
Representative plaques formed under semisolid media were immunostained, crystal violet stained 
or photographed unstained. Scale bar 300µm. (Original magnification: 40× ). (c) Average plaque 
expansion speed on BS-C-1 is indicated by the solid line. The expansion of the leading edge of 
plaques was monitored from 16-56 h.p.i. using live-cell microscopy. One-way ANOVA (n=53, 
P<0.0001) and Tukey pairwise test (*** p<0.001). (d-f) Average area of immunostained plaques 
formed under semisolid media on BS-C-1, RK13 or IEC-6 is indicated by the solid line. One-way 
ANOVA (n=20) and Tukey pairwise test (** p<0.01, ***p<0.001). (e)  
 
Fig 2: Deletion of F5L does not affect replication in vitro. (a) Single step growth analysis 
(m.o.i.=5) in BS-C-1, cell associated virus is shown. (b)  Multiple step growth analysis (m.o.i.=0.01) 
in BS-C-1, cell associated virus shown in black, virus in the supernatant is in grey. Data points are 
representative of 3 independent wells. Mean ± SEM (c) Average virus yield per plaque 72hpi after 
infection of BS-C-1 with approximately 50pfu/well is indicated by the solid line. Cell associated 
virus shown in black, virus in the supernatant is in grey.   
 
FIG 3: Localization of F5. HeLa cells were infected with VACVWR/F5LGFP (m.o.i. = 5) fixed at 8 
h.p.i., stained with either Alexa Fluor 568-phalloidin (Aph, actin), anti -β-catenin (cell-to-cell 
junctions), anti-phosphotyrosine (focal adhesions) or anti-cortactin (actin-cytoskeleton 
rearrangements) along with DAPI or anti-VACV-B5 (B5) (row 3) and imaged (100x objective) to 
analyse the localization of F5L-GFP. 
 
FIG 4: F5 does not affect formation of actin tails, or calcium independent cell adhesion. (a) 
Length of individual actin tails (n=74) were measured from micrographs of infected HeLa cells 
(100x objective). 8 h.p.i. nonpermeabilized cells were stained with anti-B5 (green) and Alexa Fluor 
568-phalloidin (red) to identify extracellular virus and virus-induced actin tails. Solid line indicates 
mean. N.s., no significant difference was found between the means. (b) Ca2+ independent cell 
adhesion. Monolayers of BS-C-1 cells infected (m.o.i.=3) or mock infected, were treated with 
10mM EDTA at 18 h.p.i. Percentage of rounded up cells was calculated from three micrographs 
per time point. At least 155 cells were counted in each micrograph (*** Mock infected cells 
significantly different to infected cells, p<0.001, Two-way ANOVA, Bonferroni post test)  
 
FIG 5: F5L is not required for VACV-induced cell migration. Wound healing assay: Wounds 
were created 1 h.p.i. in serum starved BS-C-1 monolayers. 24 h.p.i. cells were stained with DAPI 
(blue) and Alexa Fluor 568-phalloidin (red). (a) Dotted lines indicate average wound size as 
determined for mock infected cells, the viruses used for infection are shown above each 
micrograph. (b-c) Number of cells with DAPI-stained nuclei within the average wound size for the 
viruses noted on the x-axis. Means are indicated by solid lines. (b) One-way ANOVA (P<0.0001) 
and Tukey pairwise test (*** p<0.05). (c) One-way ANOVA (P<0.0001) and Tukey pairwise test (*** 
p<0.05). 
 
FIG 6: Virus infection is required for stability and the putative cytoplasmic carboxyl-terminal 
of F5 is not required for function. (a) Flow cytometry analysis of 293A cells transfected with 
vectors expressing GFP fused to VACVWR-length F5L (pEGFP-N1::F5L), GFP fused to MVA-
length F5L (pEGFP-N1::F5L218) or GFP only (pEGFP-N1), then infected with VACVWRΔF5L 
(black line) or mock infected (grey shaded). (b) Typical plaque morphology on 293A cell in the 
presence or absence of F5 provided by VACV or complemented by a transfected plasmid 
expressing F5 under its natural promoter. Cells were infected with either VACVWR (right pair) or 
VACVWRΔF5L (left pair), then transfected with vectors containing full length F5L fused to GFP 
(F5LGFP) or an empty control vector. mCherry under the VACV pSS, marks virus-infected cells. 
(c) As for b, except various deletions of F5 were expressed. The deletions are shown on the line 
diagram (SS, signal sequence; TM, transmembrane domain), with aa deleted noted above each 
micrograph.   
 
FIG 7: Deletion of F5L does not affect the virulence of VACVWR after intradermal infection. 
8 week old BALB/c mice were infected with VACVWR, VACVWRΔF5L or VACVWRF5Lrev by 
intradermal injection into the ear pinnae. (a) Lesion size estimated daily to the nearest 0.5mm after 
infection with 1x104p.f.u. (n=6). Data points are mean ± SEM. (b) Virus titer in the infected ear 5 
days p.i. with 1x104p.f.u. (n=3) or 1x102p.f.u. (n=6). Titers for individual mice are shown by the 
symbols and average (± SEM) by solid lines.  
 
FIG 8: Deletion of F5L does not affect the virulence of VACVWR after intranasal infection. (a) 
Groups of BALB/c mice received 1×104 (left) or 1×103 (right) p.f.u. of VACVWR, VACVWRΔF5L or 
VACVWRF5Lrev (n=6) or PBS (mock; n=3) intranasally and were weighed daily. Average weights 
±SEM, expressed as a percentage of baseline are shown. In the 1×104 p.f.u. experiment, one 
mouse was euthanized from each infected group due to weight loss exceeding 30% of baseline (d9 
for ΔF5L and rev and d10 for WR). Data are representative of 3 and 2 experiments with doses of 
1×104 and 1×103 p.f.u., respectively. (b) Mice were infected with 1×104 p.f.u. and infectious titers 
determined on days 3, 7 and 10 p.i.. Titers for individual mice are shown by the symbols and 
averages with solid lines. The limit of detection (dashed line) was 20 p.f.u. for lungs and brain and 
4 p.f.u. for spleen. 
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Fig 1: Deletion of F5L affects plaque phenotype on several cell lines. Plaque formation 
on BS-C-1, RK13, IEC-6 or NIH3T3 cells by VACVWR, VACVWRΔF5L and 
VACVWRF5Lrev. (a&b) Representative plaques formed under semisolid media at 72hpi 
were immunostained,  crystal violet stained or photographed unstained. Scale bar 300 
µm.(Original magnification: 40×) (c) Average plaque expansion speed on BS-C-1 is indicated 
by the solid line. The expansion of the leading edge of plaques was monitored from 16-56 
h.p.i. using live-cell microscopy. One-way ANOVA (n=53, P<0.0001) and Tukey pairwise test 
(*** p<0.001). (d-f) Average area of immunostained plaques formed under semisolid media 
on BS-C-1, RK13 or IEC-6 are indicated by the solid line. One-way ANOVA (n=20) and 
Tukey pairwise test (** p<0.01, ***p<0.001). 
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Fig 2: Deletion of F5L does not affect 
replication. in vitro (a) Single step growth 
analysis (m.o.i.=5) in BS-C-1, cell associated virus 
is shown.  (b) Multiple step growth analysis 
(m.o.i.=0.01) in BS-C-1, cell associated virus 
shown in black, virus in the supernatant is in grey.  
Data points are representative of 3 independent 
wells. Mean ± SEM (c) Average virus yield per 
plaque 72hpi after infection of BS-C-1 with 
approximately 50pfu/well is indicated by the solid 
line. Cell associated virus shown in black, virus in 
the supernatant is in grey.   
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FIG 3: Localization of F5. HeLa cells were infected with VACVWR/F5LGFP (m.o.i. = 5) fixed at 8 
h.p.i., stained with either Alexa Fluor 568-phalloidin (Aph, actin), anti -β-catenin (cell-to-cell 
junctions), anti-phosphotyrosine (focal adhesions) or anti-cortactin (actin-cytoskeleton 
rearrangements) along with DAPI or anti-VACV-B5 (B5) (row 3) and imaged (100x objective) to 
analyse the localization of F5L-GFP. 
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FIG 4: F5 does not affect formation of actin tails, or calcium independent cell 
adhesion. (a) Length of individual actin tails (n=74) were measured from micrographs of 
infected HeLa cells (100x objective). 8 h.p.i. nonpermeabilized cells were stained with anti-
B5 (green) and Alexa Fluor 568-phalloidin (red) to identify extracellular virus and virus-
induced actin tails. Solid line indicates mean. (b) Ca2+ independent cell adhesion. 
Monolayers of BS-C-1 cells infected (m.o.i.=3) or mock infected, were treated with 10mM 
EDTA at 18 h.p.i. Percentage of rounded up cells was calculated from three micrographs per 
time point. At least 155 cells were counted in each micrograph (*** Mock infected cells 
significantly different to infected cells, p<0.001, Two-way ANOVA, Bonferroni post test) 
n.s. 
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FIG 5: F5L is not required for VACV-induced cell migration. Wound healing assay: 
Wounds were created 1 h.p.i. in serum starved BS-C-1 monolayers. 24 h.p.i. cells were 
stained with DAPI (blue) and Alexa Fluor 568-phalloidin (red). (a) Dotted lines indicate 
average wound size as determined for mock infected cells. (b-c) Mean number of cells with 
DAPI-stained nuclei within the average wound size is indicated by the solid line. (b) One-
way ANOVA (P<0.0001) and Tukey pairwise test (*** p<0.05). (c) One-way ANOVA 
(P<0.0001) and Tukey pairwise test (*** p<0.05). 
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FIG 6: Virus infection is required for stability and the cytoplasmic carboxyl-terminal of F5 
is not required for function. (a) Flow cytometry analysis of 293A cells transfected with vectors 
expressing GFP fused to WR-length F5L (pEGFP-N1::F5L), GFP fused to MVA-length F5L 
(pEGFP-N1::F5L218) or GFP only (pEGFP-N1), then infected with VACVWRΔF5L (black line) or 
mock infected (grey shaded). (b) Typical plaque morphology on 293A cell in the presence or 
absence of F5 provided by VACV or complemented by a transfected plasmid expressing F5 
under its natural promoter. Cells were infected with either VACVWR (right pair) or 
VACVWRΔF5L (left pair), then transfected with vectors containing full length F5L fused to GFP 
(F5LGFP) or an empty control vector. mCherry under the VACV pSS, marks virus-infected cells. 
(c) As for b, except various deletions of F5 were expressed. The deletions are shown on the line 
diagram (SS, signal sequence; TM, transmembrane domain), with aa deleted noted above each 
micrograph.  
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FIG 7: Deletion of F5L does not affect the virulence of VACVWR after intradermal 
infection. 8 week old BALB/c mice were infected with VACVWR, VACVWRΔF5L or 
VACVWRF5Lrev by intradermal injection into the ear pinnae. (a) Lesion size estimated daily 
to the nearest 0.5mm after infection with 1x104p.f.u. (n=6). Data points are mean ± SEM. (b) 
Virus titer in the infected ear 5 days p.i. with 1x104p.f.u. (n=3) or 1x102p.f.u. (n=6). Titers for 
individual mice are shown by the symbols and average (± SEM) by solid lines. 
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FIG 8: Deletion of F5L does not affect the virulence of VACVWR after intranasal infection. 
(a) Groups of BALB/c mice received 1×104 (left) or 1×103 (right) p.f.u. of VACVWR, 
VACVWRΔF5L or VACVWRF5Lrev (n=6) or PBS (mock; n=3) intranasally and were weighed 
daily. Average weights ±SEM, expressed as a percentage of baseline are shown. In the 1×104 
p.f.u. experiment, one mouse was euthanised from each infected group due to weight loss 
exceeding 30% of baseline: (d9 for ΔF5L and rev and d10 for WR). Data are representative of 3 
and 2 experiments with doses of 1×104 and 1×103 p.f.u., respectively. (b) Mice were infected with 
1×104 p.f.u. and infectious titers determined on days 3, 7 and 10 p.i.. Titers for individual mice are 
shown by the symbols and averages with solid lines. The limit of detection (dashed line) was 20 
p.f.u. for lungs and brain and 4 p.f.u. for spleen. 
VACV WR F5L amino acid sequence 
Residues which vary between the VACV strains shown below are marked. 
MGTNGVRVFV ILYLLAVCGC IEYDVDDNVH ICTHTNVSHI NHTSWYYNDK  50 
VIALATEDKT SGYISSFIKR VNISLTCLNI SSLRYEDSGT YKGVSHLKDG  100 
VIVTTTMNIS VKANIIDLTG RVRYLTRNYC EVKIRCEITS FALNGSTTPP  150 
HMILGTVDKW KYLPFPTDDY RYVGELKRYI SGNPYPTESL ALEISSTFNR  200 
FTIVKNLNDD EFSCYLFSQN YSFHKMLNVR NICESEWEAL NNNNDNSSSM  250 
PASHNNLAND LSSMMSQLQN DNDDNNDYSA PMNVDNLIMI VLITMLSIIL  300 
VIIVVIAAIS MYKRSKYRHI DN       322 
 
Amino acid substitutions in F5 homologues in VACV strains 
Position 
(WR) 
WR1 Copenhagen1 CVA1 MVA1 Lister1 Acam20001 Ankara2 
005 Gly Val Gly Gly Gly Gly Gly 
036 Asn Asp Asn Asn Asn Asn Asp 
218 Ser Ser Ser Pro Ser Ser Ser 
229 Val Ala Ala  Val Val Ala 
231 Asn His His  Asn Asn His 
236 Glu Glu Glu  Lys Lys Glu 
238 Glu Lys Glu  Lys Lys Glu 
244 Asn deleted Asn  deleted deleted deleted 
247 Ser Ala Ser  Ala Ala Ala 
262 Ser Ser Ser  Ser Phe Ser 
273 Asp Asp Asn  Asp Asp Asp 
275 Asn Asn deleted  Asn Asn Asn 
276 Asn Asn deleted  Asn Asn Asn 
277 Asp Asp deleted  Asp Asp Asp 
314 Arg Lys Arg  Arg Lys Arg 
 
1Sequences based on published whole genome sequences: GenBank Accession numbers: WR: 
NC_006998; Copenhagen: M35027; CVA: AM501482; MVA: U94848; Lister_107: DQ121394; 
Acam2000: AY313847. 
2The F5L homologue from Ankara was sequenced (Dobson & Tscharke, 2014).  
 
Figure S1. Amino acid sequence variation in F5from WR and six other VACV strains. Above: 
The sequence of F5 from strain WR with amino acids that are different in the other strains highlighted 
in grey and underlined. Below, a table summarizing the changes relative to WR for each of the six 
strains listed. 
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Figure S2: Insertion of F5-eGFP into WRΔF5L restores normal plaque morphology. 
Plaques formed on BS-C-1 cells by VACVWR, VACVWRΔF5L and VACVWR/F5LGFP under 
semisolid media at 72 h.p.i..  (a) Representative plaques were immunostained,  crystal violet 
stained or photographed unstained. Scale bar 300 µm.(Original magnification: 40× ) (b) 
Average area of immunostained plaques are indicated by the solid line (72h.p.i.). One-way 
ANOVA (n=20) and Tukey pairwise test (***p<0.001). 
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Figure S3: eGFP fluorescence in cells transfected with F5-eGFP expressed in trans 
from plasmids  in virus infected cells. Cells were infected with VACVWRΔF5L, then 
transfected with an empty control vector (pSSmCB) or vectors containing full length F5L 
fused to GFP (F5L-eGFP) or variants of this contrstruct with portions of F5 deleted (aa 
deleted shown above each image). Red fluorescence is from mCherry under the VACV pSS 
and marks all cells that are transfected and infected. Fluorescence from eGFP demonstrates 
expression of each of the F5-expressing variants.  
